Promoter Docon releases pledge on 1.75 crore Thyrocare shares
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts less than Nifty Microcap 250 and 6.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Docon Technologies, promoter of Thyrocare Technologies, released the pledge on 1,75,00,000 equity shares (about 10.99% of capital) on August 11, 2026. Shares were pledged with Catalyst Trusteeship as security for NCDs issued by parent API Holdings. Docon's total holding stays unchanged at 9,69,69,696 shares (60.92%). Encumbered shares fell from 60.92% to 49.93% of capital. Outstanding NCD principal is about INR 10,500 million.
Pledge release frees up about 10.99% of promoter shares from encumbrance, lowering pledge risk. Mildly positive for stock.